TOKYO and CAMBRIDGE, Mass., Dec 5, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (AD)*.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**), as well as insoluble Aβ aggregates (fibrils) which are amajor component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved and being marketed in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and Great Britain.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study,LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2)Approximately 1.3 million people in Mexico are estimated to suffer from AD, accounting for 60-70% of all dementia diagnoses.3 AD most commonly affects individuals over the age of 65.(3)Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai and Biogen will co-commercialize and co-promote LEQEMBI in Mexico.*Collectively referred to mild cognitive impairment due to AD or mild AD dementia.**Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(4) Protofibrils cause injury toneurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(5)About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulingamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab is approved and being marketed in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates and Great Britain for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) ormild dementia stage of disease (collectively referred to as early AD). The treatment’s approvals in these countries was based onPhase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The most common adverse events (>10%) in the lecanemab group were infusion reactions,ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.Lecanemab is under regulatory review in 16 countries and regions, including the European Union. In November 2024, thetreatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normaland have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti- amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisaiserves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializingand co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&Dfacilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseaseswith high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S.headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters:Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com.Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof;the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, andonly a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in suchstatements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficultto complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse toapprove or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and otherproprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and thirdparty collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factorsthat could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in otherreports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.References(1) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: www.eisai.com/news/2022/news202285.html(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. www.nejm.org/doi/full/10.1056/NEJMoa2212948(3) Secretaría de Salud. Enfermedad de Alzheimer, demencia más común que afecta a personas adultas mayores. Oct 2021. https://tinyurl.com/ttv486xx(4) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(5) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL : +81 (0)3-3817-5120INVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comBiogen Inc.Stephen Amato+ 1-781-464-2442IR@biogen.com Copyright 2024 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, Dec 4, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO Corporation has recently signed a Memorandum of Understanding (MOU) with Canatu to advance the practical application of carbon nanotube technology. By strengthening their partnership, the two companies aim to deepen their collaboration to contribute to the advancement of autonomous driving technology and the realization of carbon neutrality.As autonomous driving technology continues to evolve, vehicles must accurately detect their surroundings using cameras and other sensors. However, issues such as frost and condensation can obstruct visibility and complicate detection. To address these challenges, DENSO is developing products that utilize transparent conductive films made from flexible, transparent materials. Carbon nanotube technology is key to these developments.Carbon nanotubes are carbon-based materials with extremely fine structures, characterized by high strength, light weight, and excellent electrical and thermal conductivity. They hold great promise for a wide range of applications. Canatu has innovative technology that enables the efficient production of high-purity carbon nanotubes using proprietary materials and has strengths in transparent conductive film formation.DENSO has been collaborating with Canatu by combining Canatu’s advanced transparent conductive film technology with DENSO’s expertise in automotive technology and mass production. In April this year, the companies successfully developed a reactor* at Canatu’s production facility in Finland, significantly enhancing the productivity of carbon nanotubes. They have also been jointly developing transparent heaters for vehicle cameras and windshields. Moving forward, DENSO and Canatu will continue to drive efforts toward the commercialization of transparent heaters while also expand their application to environmental technologies. Their goal is to establish technologies that contribute to carbon neutrality.Key Areas of CollaborationDENSO and Canatu will accelerate initiatives in the following three areas to achieve practical applications of carbon nanotube technology:1. Research and DevelopmentDevelop new applications, including transparent heaters and solar power technologies, utilizing carbon nanotubes.2. Mass Production TechnologiesCollaborate on improving manufacturing equipment and processes to achieve the quality required for mass production.3. Global Supply Chain DevelopmentBegin exploring the establishment of a reliable supply system to ensure the stable and consistent delivery of high-quality products.DENSO will continue advancing technology development in collaboration with partners across various fields, contributing to sustainable mobility for people and the planet.*Reactor: Equipment used for manufacturing carbon nanotubes. Copyright 2024 JCN Newswire via SeaPRwire.com.